Immunological response to diphtheria and tetanus toxoids

The immunological response to diphtheria and tetanus toxoids is a physiological process involving the activation of the adaptive immune system to produce protective antibodies (CDC, 2020). It is triggered by the administration of inactivated toxins (toxoids) derived from Corynebacterium diphtheriae and Clostridium tetani (WHO, 2017). This response involves antigen presentation by dendritic cells, which subsequently activates CD4+ T helper cells and B cells to undergo clonal expansion and differentiation into plasma cells. The primary outcome is the secretion of high-affinity IgG antibodies that neutralize the pathogenic toxins before they can bind to cellular receptors. In clinical medicine, this response is frequently used as a diagnostic tool to evaluate the competency of a patient's humoral immune system, particularly in cases of suspected primary immunodeficiency (Orange et al., 2012). It is also the primary measure of efficacy for DTaP, Tdap, and other related vaccines. Protective thresholds are well-established, with antibody concentrations of 0.1 IU/mL or higher typically indicating long-term immunity (WHO, 2017). While the toxoids act as the antigens, the response itself is a multi-component biological pathway rather than a single therapeutic target.

Other names

Diphtheria and tetanus antibody responseDT/TT immune responseHumoral immunity to diphtheria and tetanus

Induction of active immunity through the production of specific neutralizing IgG antibodies against diphtheria and tetanus toxins (CDC, 2020).